{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T08:13:30Z","timestamp":1794903210239,"version":"4.9.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,23]]},"DOI":"10.7759\/cureus.93065","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T02:22:45Z","timestamp":1758680565000},"source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and Safety of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Spinal Fusion Outcomes: A Comprehensive Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Mohamed","family":"Zahed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Elmesalmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled F","family":"Al-Kharouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara E","family":"Elbahnasawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziad","family":"El Menawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salam","family":"Elhanash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Odeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nour","family":"Elnaggar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Hesham Gamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud M","family":"Elhady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jor.2016.10.029","article-title":"Spinal fusion surgery: a historical perspective","volume":"14","author":"Tarpada SP","year":"2017","unstructured":"Tarpada SP, Morris MT, Burton DA. Spinal fusion surgery: a historical perspective. J Orthop. 2017, 14:134-6. 10.1016\/j.jor.2016.10.029","journal-title":"J Orthop"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xnsj.2023.100302","article-title":"Predictive factors of symptomatic lumbar pseudoarthrosis following multilevel primary lumbar fusion","volume":"17","author":"Shahzad H","year":"2024","unstructured":"Shahzad H, Ahmad M, Singh VK, Bhatti N, Yu E, Phillips FM, Khan SN. Predictive factors of symptomatic lumbar pseudoarthrosis following multilevel primary lumbar fusion. N Am Spine Soc J. 2024, 17:100302. 10.1016\/j.xnsj.2023.100302","journal-title":"N Am Spine Soc J"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/BRS.0000000000002822","article-title":"Trends in lumbar fusion procedure rates and associated hospital costs for degenerative spinal diseases in the United States, 2004 to 2015","volume":"44","author":"Martin BI","year":"2019","unstructured":"Martin BI, Mirza SK, Spina N, Spiker WR, Lawrence B, Brodke DS. Trends in lumbar fusion procedure rates and associated hospital costs for degenerative spinal diseases in the United States, 2004 to 2015. Spine (Phila Pa 1976). 2019, 44:369-76. 10.1097\/BRS.0000000000002822","journal-title":"Spine (Phila Pa 1976)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/CORR.0000000000002576","article-title":"Projections from surgical use models in Germany suggest a rising number of spinal fusions in patients 75 years and older will challenge healthcare systems worldwide","volume":"481","author":"Heck VJ","year":"2023","unstructured":"Heck VJ, Klug K, Prasse T, et al.. Projections from surgical use models in Germany suggest a rising number of spinal fusions in patients 75 years and older will challenge healthcare systems worldwide. Clin Orthop Relat Res. 2023, 481:1610-9. 10.1097\/CORR.0000000000002576","journal-title":"Clin Orthop Relat Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3171\/2019.1.FOCUS18669","article-title":"Benefits of Enhanced Recovery After Surgery for fusion in degenerative spine surgery: impact on outcome, length of stay, and patient satisfaction","volume":"46","author":"Debono B","year":"2019","unstructured":"Debono B, Corniola MV, Pietton R, Sabatier P, Hamel O, Tessitore E. Benefits of Enhanced Recovery After Surgery for fusion in degenerative spine surgery: impact on outcome, length of stay, and patient satisfaction. Neurosurg Focus. 2019, 46:E6. 10.3171\/2019.1.FOCUS18669","journal-title":"Neurosurg Focus"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpa.2016.01.002","article-title":"Postoperative complications of spine surgery","volume":"30","author":"Swann MC","year":"2016","unstructured":"Swann MC, Hoes KS, Aoun SG, McDonagh DL. Postoperative complications of spine surgery. Best Pract Res Clin Anaesthesiol. 2016, 30:103-20. 10.1016\/j.bpa.2016.01.002","journal-title":"Best Pract Res Clin Anaesthesiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2018.08.026","article-title":"Risk of pseudoarthrosis after spinal fusion: analysis from the Healthcare Cost and Utilization Project","volume":"120","author":"Hofler RC","year":"2018","unstructured":"Hofler RC, Swong K, Martin B, Wemhoff M, Jones GA. Risk of pseudoarthrosis after spinal fusion: analysis from the Healthcare Cost and Utilization Project. World Neurosurg. 2018, 120:e194-202. 10.1016\/j.wneu.2018.08.026","journal-title":"World Neurosurg"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.5435\/00124635-200908000-00003","article-title":"Pseudarthrosis of the spine","volume":"17","author":"Raizman NM","year":"2009","unstructured":"Raizman NM, O'Brien JR, Poehling-Monaghan KL, Yu WD. Pseudarthrosis of the spine. J Am Acad Orthop Surg. 2009, 17:494-503. 10.5435\/00124635-200908000-00003","journal-title":"J Am Acad Orthop Surg"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/BRS.0000000000004115","article-title":"Pseudarthrosis following lumbar and lumbosacral fusion using the antepsoas technique","volume":"46","author":"Tannoury C","year":"2021","unstructured":"Tannoury C, Bhale R, Vora M, et al.. Pseudarthrosis following lumbar and lumbosacral fusion using the antepsoas technique. Spine (Phila Pa 1976). 2021, 46:1690-5. 10.1097\/BRS.0000000000004115","journal-title":"Spine (Phila Pa 1976)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbiomech.2010.10.021","article-title":"Challenges to bone formation in spinal fusion","volume":"44","author":"Reid JJ","year":"2011","unstructured":"Reid JJ, Johnson JS, Wang JC. Challenges to bone formation in spinal fusion. J Biomech. 2011, 44:213-20. 10.1016\/j.jbiomech.2010.10.021","journal-title":"J Biomech"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076410","article-title":"Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis","volume":"384","author":"Yao H","year":"2024","unstructured":"Yao H, Zhang A, Li D, Wu Y, Wang CZ, Wan JY, Yuan CS. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ. 2024, 384:e076410. 10.1136\/bmj-2023-076410","journal-title":"BMJ"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2024.03.011","article-title":"Glucagon-like peptide-1 receptor agonists rescued diabetic vascular endothelial damage through suppression of aberrant STING signaling","volume":"14","author":"He X","year":"2024","unstructured":"He X, Wen S, Tang X, et al.. Glucagon-like peptide-1 receptor agonists rescued diabetic vascular endothelial damage through suppression of aberrant STING signaling. Acta Pharm Sin B. 2024, 14:2613-30. 10.1016\/j.apsb.2024.03.011","journal-title":"Acta Pharm Sin B"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.22243","article-title":"Presence of a functional receptor for GLP-1 in osteoblastic cells, independent of the cAMP-linked GLP-1 receptor","volume":"225","author":"Nuche-Berenguer B","year":"2010","unstructured":"Nuche-Berenguer B, Portal-N\u00fa\u00f1ez S, Moreno P, et al.. Presence of a functional receptor for GLP-1 in osteoblastic cells, independent of the cAMP-linked GLP-1 receptor. J Cell Physiol. 2010, 225:585-92. 10.1002\/jcp.22243","journal-title":"J Cell Physiol"},{"key":"ref14","article-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins JP","year":"2008","unstructured":"Higgins JP. Cochrane Handbook for Systematic Reviews of Interventions. John Wiley Sons Ltd., Hoboken, NJ; 2008."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang A","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010, 25:603-5. 10.1007\/s10654-010-9491-z","journal-title":"Eur J Epidemiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1227\/neu.0000000000003291","article-title":"Perioperative glucagon-like peptide-1 agonist use and rates of pseudarthrosis after single-level lumbar fusion: a large retrospective cohort study","volume":"97","author":"Agrawal V","year":"2024","unstructured":"Agrawal V, Amasa S, Karabacak M, Margetis K. Perioperative glucagon-like peptide-1 agonist use and rates of pseudarthrosis after single-level lumbar fusion: a large retrospective cohort study. Neurosurgery. 2024, 97:91-7. 10.1227\/neu.0000000000003291","journal-title":"Neurosurgery"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.spinee.2025.07.010","article-title":"Association between glucagon-like peptide-1 receptor agonists and non-fusion risk after single-level anterior cervical discectomy and fusion [in press]","author":"Chang Y","year":"2025","unstructured":"Chang Y, Chi KY, Song J, Lin HM. Association between glucagon-like peptide-1 receptor agonists and non-fusion risk after single-level anterior cervical discectomy and fusion [in press]. Spine J. 2025, 10.1016\/j.spinee.2025.07.010","journal-title":"Spine J"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.xnsj.2025.100612","article-title":"Glucagon-like peptide-1 receptor agonist use prior to spinal surgery results in reduced postoperative length of stay: a propensity-score matched analysis","volume":"22","author":"Goldman SN","year":"2025","unstructured":"Goldman SN, Mani K, Scharfenberger T, et al.. Glucagon-like peptide-1 receptor agonist use prior to spinal surgery results in reduced postoperative length of stay: a propensity-score matched analysis. N Am Spine Soc J. 2025, 22:100612. 10.1016\/j.xnsj.2025.100612","journal-title":"N Am Spine Soc J"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2025.108952","article-title":"The impact of semaglutide use for weight loss on transforaminal lumbar interbody fusion outcomes","volume":"254","author":"Khalid SI","year":"2025","unstructured":"Khalid SI, Mirpuri P, Massaad E, Wang R, Elsamadicy A, Shin JH, Adogwa O. The impact of semaglutide use for weight loss on transforaminal lumbar interbody fusion outcomes. Clin Neurol Neurosurg. 2025, 254:108952. 10.1016\/j.clineuro.2025.108952","journal-title":"Clin Neurol Neurosurg"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.spinee.2025.03.023","article-title":"Semaglutide use is associated with higher rates of pseudarthrosis and dysphagia in patients undergoing posterior cervical fusion","volume":"25","author":"Ng MK","year":"2025","unstructured":"Ng MK, Mastrokostas PG, Mastrokostas LE, Tabbaa A, Johnson M, Monsef JB, Razi AE. Semaglutide use is associated with higher rates of pseudarthrosis and dysphagia in patients undergoing posterior cervical fusion. Spine J. 2025, 25:1974-80. 10.1016\/j.spinee.2025.03.023","journal-title":"Spine J"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.spinee.2024.10.011","article-title":"Semaglutide utilization associated with reduced 90-day postoperative complications following single-level posterior lumbar fusion for patients with type II diabetes","volume":"25","author":"Seddio AE","year":"2025","unstructured":"Seddio AE, Gouzoulis MJ, Vasudevan RS, et al.. Semaglutide utilization associated with reduced 90-day postoperative complications following single-level posterior lumbar fusion for patients with type II diabetes. Spine J. 2025, 25:485-93. 10.1016\/j.spinee.2024.10.011","journal-title":"Spine J"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1097\/BRS.0000000000005099","article-title":"No difference in short-term surgical outcomes from semaglutide treatment for type 2 diabetes mellitus after cervical decompression and fusion: a propensity score-matched analysis","volume":"50","author":"Tao X","year":"2025","unstructured":"Tao X, Ranganathan S, Van Halm-Lutterodt N, et al.. No difference in short-term surgical outcomes from semaglutide treatment for type 2 diabetes mellitus after cervical decompression and fusion: a propensity score-matched analysis. Spine (Phila Pa 1976). 2025, 50:515-21. 10.1097\/BRS.0000000000005099","journal-title":"Spine (Phila Pa 1976)"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jor.2025.05.018","article-title":"GLP-1 receptor agonist use in elective lumbar spine surgery: reduced pseudarthrosis rates and favorable safety profile","volume":"65","author":"Tummala S","year":"2025","unstructured":"Tummala S, Gibbs DC, Chavarria J, Alder J, Avramis I, Rizkalla JM. GLP-1 receptor agonist use in elective lumbar spine surgery: reduced pseudarthrosis rates and favorable safety profile. J Orthop. 2025, 65:227-32. 10.1016\/j.jor.2025.05.018","journal-title":"J Orthop"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1097\/BRS.0000000000005283","article-title":"Glucagon-like peptide-1 receptor agonist medications alter outcomes of spine surgery: a study among over 15,000 patients","volume":"50","author":"Wiener JM","year":"2025","unstructured":"Wiener JM, Sanghvi PA, Vlastaris K, et al.. Glucagon-like peptide-1 receptor agonist medications alter outcomes of spine surgery: a study among over 15,000 patients. Spine (Phila Pa 1976). 2025, 50:871-80. 10.1097\/BRS.0000000000005283","journal-title":"Spine (Phila Pa 1976)"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1097\/BSD.0000000000001800","article-title":"The use of semaglutide in patients undergoing lumbar fusion does not increase 90-day medical or 1-year implant complications [in press]","author":"Ghali A","year":"2025","unstructured":"Ghali A, Lawand J, Mitchell P, et al.. The use of semaglutide in patients undergoing lumbar fusion does not increase 90-day medical or 1-year implant complications [in press]. Clin Spine Surg. 2025, 10.1097\/BSD.0000000000001800","journal-title":"Clin Spine Surg"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000002492","article-title":"The impact of semaglutide on fusion rates following posterior lumbar fusion surgery in patients with type 2 diabetes","volume":"111","author":"Chang Y","year":"2025","unstructured":"Chang Y, Lin HM, Chi KY, Song J, Atwan H. The impact of semaglutide on fusion rates following posterior lumbar fusion surgery in patients with type 2 diabetes. Int J Surg. 2025, 111:4898-900. 10.1097\/JS9.0000000000002492","journal-title":"Int J Surg"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1097\/BRS.0000000000005466","article-title":"Are GLP-1 receptor agonists safe in spine surgery: a systematic review [in press]","author":"Younus I","year":"2025","unstructured":"Younus I, Garcia de Oliveira R, Fujii T, et al.. Are GLP-1 receptor agonists safe in spine surgery: a systematic review [in press]. Spine (Phila Pa 1976). 2025, 10.1097\/BRS.0000000000005466","journal-title":"Spine (Phila Pa 1976)"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1713042","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"de Boer IH","year":"2017","unstructured":"de Boer IH. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017, 377:2198. 10.1056\/NEJMc1713042","journal-title":"N Engl J Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(24)00271-7","article-title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials","volume":"13","author":"Badve SV","year":"2025","unstructured":"Badve SV, Bilal A, Lee MM, et al.. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2025, 13:15-28. 10.1016\/S2213-8587(24)00271-7","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3390\/medicina55060233","article-title":"GLP-1 receptor agonists and kidney protection","volume":"55","author":"Greco EV","year":"2019","unstructured":"Greco EV, Russo G, Giandalia A, Viazzi F, Pontremoli R, De Cosmo S. GLP-1 receptor agonists and kidney protection. Medicina (Kaunas). 2019, 55:233. 10.3390\/medicina55060233","journal-title":"Medicina (Kaunas)"},{"key":"ref32","unstructured":"FDA approves new medication for chronic weight management. (2014). Accessed. August 11, 2025: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-medication-chronic-weight-management.."},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1093\/jbmrpl\/ziae053","article-title":"Diabetes increases risk of lumbar spinal fusion complications: association with altered structure of newly formed bone at the fusion site","volume":"8","author":"Wilson C","year":"2024","unstructured":"Wilson C, Czernik PJ, Elgafy H, Khuder S, Serdahely K, Rowland A, Lecka-Czernik B. Diabetes increases risk of lumbar spinal fusion complications: association with altered structure of newly formed bone at the fusion site. JBMR Plus. 2024, 8:ziae053. 10.1093\/jbmrpl\/ziae053","journal-title":"JBMR Plus"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1177\/21925682211072849","article-title":"Obesity: an independent risk factor for complications in anterior lumbar interbody fusion? A systematic review","volume":"12","author":"Feeley A","year":"2022","unstructured":"Feeley A, McDonnell J, Feeley I, Butler J. Obesity: an independent risk factor for complications in anterior lumbar interbody fusion? A systematic review. Global Spine J. 2022, 12:1894-903. 10.1177\/21925682211072849","journal-title":"Global Spine J"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.2337\/db13-1440","article-title":"Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model","volume":"63","author":"Richards P","year":"2014","unstructured":"Richards P, Parker HE, Adriaenssens AE, et al.. Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model. Diabetes. 2014, 63:1224-33. 10.2337\/db13-1440","journal-title":"Diabetes"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1177\/1474651408100525","article-title":"Mechanisms behind GLP-1 induced weight loss","volume":"8","author":"Larsen PJ","year":"2008","unstructured":"Larsen PJ. Mechanisms behind GLP-1 induced weight loss. Br J Diabetes Vasc Dis. 2008, 8:34-41. 10.1177\/1474651408100525","journal-title":"Br J Diabetes Vasc Dis"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1378291","article-title":"Liraglutide, a glucagon-like peptide-1 receptor agonist, inhibits bone loss in an animal model of osteoporosis with or without diabetes","volume":"15","author":"Wu Z","year":"2024","unstructured":"Wu Z, Deng W, Ye Y, Xu J, Han D, Zheng Y, Zheng Q. Liraglutide, a glucagon-like peptide-1 receptor agonist, inhibits bone loss in an animal model of osteoporosis with or without diabetes. Front Endocrinol (Lausanne). 2024, 15:1378291. 10.3389\/fendo.2024.1378291","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/406594-efficacy-and-safety-of-glucagon-like-peptide-1-glp-1-receptor-agonists-for-spinal-fusion-outcomes-a-comprehensive-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T02:22:48Z","timestamp":1758680568000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/406594-efficacy-and-safety-of-glucagon-like-peptide-1-glp-1-receptor-agonists-for-spinal-fusion-outcomes-a-comprehensive-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,23]]},"references-count":37,"URL":"https:\/\/doi.org\/10.7759\/cureus.93065","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,23]]}}}